Steven H. Holtzman has been the Chief Business Officer of Millennium Pharmaceuticals, Inc. (NASDAQ: MLNM) since early 1994 in which role he has had management responsibility for the Company's activities in the areas of: business development, M&A, licensing, intellectual property and corporate law, human resources, finance and corporate communications, government relations and public policy.

Since its founding in mid-1993, Millennium has grown to over 1,500 employees and is ranked among the top ten companies in the biotechnology industry in market capitalization and revenues. Millennium is a pioneer and leader in the identification of the genetic basis of common human diseases and the use of such information to develop therapeutic and diagnostic products directed to the cause, not merely the symptoms, of disease.

Prior to joining Millennium, from 1986-1994, Mr. Holtzman was a founder and the first employee of DNX Corporation, the first commercial enterprise devoted to the development of biomedical and pharmaceutical applications of transgenic animal technology. DNX pioneered the development of genetically engineered laboratory animals as better models of human disease and the development of genetically engineered pigs as a potential source of organs for transplantation to humans. At DNX, Mr. Holtzman was Executive Vice President and a Member of the Executive Committee of the Board of Directors as well as President of DNX Bio-Therapeutics, Inc., DNX's wholly-owned biotechnology subsidiary (now Nextran, a subsidiary of Baxter Healthcare).

Prior to DNX, in the early 1980's, Mr. Holtzman conceived of and was the founding Executive Director of the Ohio Edison Program, the nation's first state government program directed to achieving economic development through funding young technology-based ventures and university/industry collaborative research and development efforts. Over time, the Edison Program became viewed as a model state government initiative, widely emulated by over 40 states.

In the late 1970's, Mr. Holtzman was an instructor and tutor in moral philosophy and the philosophy of language at Corpus Christi College, Oxford University, U.K

In 1995, Mr. Holtzman was a founding Co-Chair and is a current member of the Biotechnology Industry Organization (BIO) Bioethics Committee. In 1998, he served as a member of the Working Group of the Advisory Committee to the Director of the NIH on Access to Research Tools. In 1996, he was appointed by President Clinton as the sole individual from the pharmaceutical or biotechnology industry to serve on the National Bioethics Advisory Commission, the principal advisory body to the President and Congress on ethical issues in the biomedical and life sciences. In late-1999, he was asked to serve a second term on the Commission. Since 1999, he has served as a Trustee of The Hastings Center for Bioethics.

Mr. Holtzman received his B.A. in Philosophy from Michigan State University and his B.Phil. graduate degree in Philosophy from Oxford University, which he attended as a Rhodes Scholar. He is a frequent invited speaker at biotechnology and pharmaceutical industry conferences, NIH and NAS symposia, and business schools on the subjects of structuring alliances between biotechnology and pharmaceutical companies, biotechnology entrepreneurship, bioethics and patents and intellectual property protection in the life sciences.